Navinci, formerly known as Olink Biosciences, has a proud history as developers of the first commercial in situ proximity ligation assays. The proximity ligation technology can be used to monitor interactions or modifications of endogenous proteins directly in individual cells and tissues, to reveal the cellular and molecular architecture and its responses to disturbances. The Naveni proximity ligation assays are based on a new, proprietary technology providing higher sensitivity and less unspecific background than traditional PLA.
Empowering in situ research
The Naveni proximity ligation platform pushes the boundries of fluorescence-based in situ methodology, enabling researchers to get the maximum information from every analysis by localizing and quantifying proteins, their interactions and modifications, in situ at the molecular level. Increased sensitivity compared to conventional in situ PLA, enables detection of very low abundant proteins and ensures that proteins can be investigated without the need to over-express, or in any way modify the native environment of the cell.
Designed to offer the ultimate flexibility regarding target selection and experimental design.
- Simple protocol based on secondary detection using our proprietary Navenibodies
- Works with traditional in situ equipment and workflows
- Sensitive fluorescence readout
- Each kit comes with three detection fluorophores (Atto488, TEX615, and Atto647N).
“To my impression it is a lot better than every other PLA we have done before. The negative controls are nearly blank for the first time ever. This is a huge advantage of your kit because this was the main point with which we always struggled when analyzing the assay in a quantitative way”.
Dr. Stefan Pusch,
What we do
Navinci develops proprietary high-performance kits for the detection of proteins, their modifications and interactions in tissue & cell samples.
How we do it
The Naveni platform pushes the boundaries of fluorescence staining by enabling specific and sensitive proximity ligation detection from two primary antibodies.